To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

September 18, 2023

FDA Widens Temodar's Approval to Fight Another Brain Cancer Type

The FDA has allowed the use of Temodar for two new purposes in adults with a type of brain tumor called anaplastic astrocytoma. Temodar is a drug that was first approved by the FDA in 1999 to treat adults with a different type of brain tumor called glioblastoma.

temodar pills

Now, the FDA says that adults with newly diagnosed anaplastic astrocytoma can use Temodar along with other treatments, and it can also be used to treat adults with anaplastic astrocytoma that haven't responded well to other treatments.

This change is part of a program called Project Renewal, which focuses on updating information about older cancer drugs. Some common side effects of Temodar include hair loss, tiredness, nausea, vomiting, headaches, constipation, loss of appetite, and seizures.

Shreya Prakash photo

Shreya Prakash
Clinical Research Coordinator
& Patient Navigator
The EndBrainCancer Initiative
16150 NE 85th St., Suite #201
Redmond, WA 98052


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram